Table 4.
Correlations between the overall survival and clinicopathological factors
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age (≥70 years vs. <70 years) | 2.366 | 1.058–5.289 | 0.036 | 3.355 | 1.373–8.200 | 0.008 |
| Gender (Male vs. Female) | 1.250 | 0.565–2.765 | 0.582 | |||
| Tumor depth (T4 vs. T1–3) | 1.387 | 0.616–3.124 | 0.430 | |||
| Histological type (Poorly, Mucinous vs. Well, Moderately) | 1.660 | 0.495–5.573 | 0.412 | |||
| Lymphatic involvement (Positive vs. Negative) | 2.461 | 0.733–8.258 | 0.145 | |||
| Venous involvement (Positive vs. Negative) | 2.987 | 1.306–6.831 | 0.010 | 3.911 | 1.540–9.936 | 0.004 |
| Lymph node metastasis (Positive vs. Negative) | 2.641 | 1.135–6.148 | 0.024 | 1.729 | 0.699–4.273 | 0.236 |
| CEA (>5 ng/ml vs. ≤5 ng/ml) | 2.563 | 1.149–5.717 | 0.021 | 1.258 | 0.513–3.085 | 0.616 |
| CA19–9 (>37 U/ml vs. ≤37 U/ml) | 3.117 | 1.226–7.928 | 0.017 | 2.127 | 0.720–6.281 | 0.172 |
| TAM (High vs. Low) | 2.841 | 1.128–7.152 | 0.027 | 4.123 | 1.464–11.610 | 0.007 |
HR hazard ratio, CI confidence interval, TAMs tumor-associated macrophages, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9